OverviewSuggest Edit

Arix Bioscience is a provider of venture capital funding services intended to build international group of healthcare and life science businesses. Its services encourage investment in early-stage companies by offering tax benefits in return for the additional risks involved, providing both start-up and later-stage companies with specialized fund management service.

TypePublic
Founded2015
HQLondon, GB
Websitearixbioscience.com

Latest Updates

Employees (est.) (Nov 2020)15
Revenue (FY, 2018)£1.3 M(-28%)
Share Price (Nov 2020)£1.5
Cybersecurity ratingAMore

Key People/Management at Arix Bioscience

Naseem Amin

Naseem Amin

Executive Chairman
Robert Lyne

Robert Lyne

Chief Operating Officer and General Counsel
Jonathan Tobin

Jonathan Tobin

Managing Director
Mark Chin

Mark Chin

Investment Director
Noor Lalani

Noor Lalani

Public Markets Investment Director
Christian Schetter

Christian Schetter

Managing Director
Show more

Arix Bioscience Office Locations

Arix Bioscience has an office in London
London, GB (HQ)
20 Berkeley Square, Mayfair
Show all (1)

Arix Bioscience Financials and Metrics

Arix Bioscience Revenue

Arix Bioscience's revenue was reported to be £1.33 m in FY, 2018
GBP

Revenue (FY, 2018)

1.3m

Net income (FY, 2018)

36.9m

EBIT (FY, 2018)

40.8m

Market capitalization (17-Nov-2020)

204.8m

Closing stock price (17-Nov-2020)

1.5

Cash (31-Dec-2018)

91.2m

EV

113.6m
Arix Bioscience's current market capitalization is £204.8 m.
GBPFY, 2017FY, 2018

Revenue

1.9m1.3m

Depreciation and amortization

218.0k216.0k

EBIT

(3.6m)40.8m

EBIT margin, %

(193%)3073%
GBPFY, 2017FY, 2018

Cash

74.9m91.2m

Accounts Receivable

275.0k1.7m

Current Assets

76.2m93.4m
GBPFY, 2017FY, 2018

Cash From Operating Activities

(8.8m)(11.1m)

Cash From Investing Activities

(50.2m)(115.4m)

Cash From Financing Activities

105.1m82.2m

Net Change in Cash

46.0m(44.2m)
GBPFY, 2017

Revenue/Employee

137.6k

Financial Leverage

1 x
Show all financial metrics

Arix Bioscience Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Arix Bioscience Online and Social Media Presence

Embed Graph

Arix Bioscience News and Updates

Arix Bioscience plc: Arix to Present at the Proactive One2One Biotech Forum

LONDON, June 9, 2020 /PRNewswire/ -- Arix Bioscience plc ("Arix") (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that Jonathan Tobin, PhD, Managing Director, will present at the Proactive One2One Virtual...

Arix Bioscience plc : Imara Files for Proposed Initial Public Offering in the United States

LONDON, Feb. 17, 2020 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience"), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that one of its portfolio companies, Imara Inc., ("Imara"), has filed a...

Arix Bioscience plc: 2019 Capital Markets Day

LONDON, Oct. 3, 2019 /PRNewswire/ -- Arix Bioscience plc ("Arix") (LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies, is hosting its 2019 Capital Markets Day from 1:45pm today Thursday, 3rd October 2019 in London. The Capital...

Arix Bioscience plc: Arix Co-leads EUR 20 Million Series A Investment Round in STipe Therapeutics

LONDON, Sept. 30, 2019 /PRNewswire/ -- Arix Bioscience plc ("Arix") (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that it has invested in new portfolio company STipe Therapeutics ("STipe"), a company...

Arix Bioscience plc: Amplyx Unveils Expanded Pipeline and Reports Phase 2 Data from Lead Programme

LONDON, Sept. 17, 2019 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies, today notes the following updates from its portfolio company Amplyx Pharmaceuticals ("Amplyx"), a biotech...

Arix Bioscience plc - Imara Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering in the United States

LONDON, Sept. 13, 2019 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company Imara, Inc. ("Imara"), has confidentially submitted a draft...
Show more

Arix Bioscience Blogs

Autolus announces update on AUTO4 and AUTO5 programmes

LONDON, 3 December 2018: Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation notes its portfolio company, Autolus Therapeutics plc (NASDAQ: AUTL) (“Autolus”), announced that the first patient has been dosed in its Phase 1/2 LibrA T1 cli…

Autolus presents initial AUTO3 clinical data at ASH

LONDON, 3 December 2018: Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation notes that its portfolio company, Autolus Therapeutics plc (NASDAQ: AUTL) (“Autolus”), announced updated results from its ongoing AUTO3 Phase 1/2 clinical tria…

Pharmaxis releases positive results of Phase 1 clinical trial for second LOXL2 inhibitor compound

LONDON, 15 November 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, is pleased to note that Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis, has announced positive…

Aura Biosciences reports positive Phase 1b/2 clinical data for AU-011

Multiple doses of AU-011 are well tolerated, with vision preservation observed at 12 to 18 months All Patients met preliminary efficacy endpoint to date with evidence of biological activity Aura plans to initiate a pivotal Phase 3 clinical study LONDON, 30 October 2018: Arix Bioscience plc ("Arix") …

Pharmaxis releases positive results of Phase 1 clinical trial for LOXL2 inhibitor compound

LONDON, 11 October 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, is pleased to note that its Group Business, Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis, tod…

Update on LogicBio proposed initial public offering in the United States

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 LONDON, 10 October 2018 Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, today notes that LogicBio Therapeutics Inc.(“Log…
Show more

Arix Bioscience Frequently Asked Questions

  • When was Arix Bioscience founded?

    Arix Bioscience was founded in 2015.

  • Who are Arix Bioscience key executives?

    Arix Bioscience's key executives are Naseem Amin, Robert Lyne and Jonathan Tobin.

  • How many employees does Arix Bioscience have?

    Arix Bioscience has 15 employees.

  • What is Arix Bioscience revenue?

    Latest Arix Bioscience annual revenue is £1.3 m.

  • What is Arix Bioscience revenue per employee?

    Latest Arix Bioscience revenue per employee is £88.5 k.

  • Who are Arix Bioscience competitors?

    Competitors of Arix Bioscience include Tranquis Therapeutics, Juvenescence and Omega Healthcare Investors.

  • Where is Arix Bioscience headquarters?

    Arix Bioscience headquarters is located at 20 Berkeley Square, Mayfair, London.

  • Where are Arix Bioscience offices?

    Arix Bioscience has an office in London.

  • How many offices does Arix Bioscience have?

    Arix Bioscience has 1 office.